Key takeaways
Dupixent (dupilumab) and Adbry (tralokinumab) are both biologic medications used to treat moderate-to-severe eczema. They work by targeting proteins in the immune system to reduce inflammation. However, they have some important differences. Dupixent is approved for a wider range of conditions, including asthma and sinus congestion with nasal polyps, whereas Adbry is specifically for eczema. Dupixent can be used in children as young as 6 months, while Adbry is only for those 12 years and older. Dupixent is typically injected every 1 to 4 weeks, while Adbry is injected every 2 to 4 weeks. Common side effects of Dupixent include injection site reactions and eye inflammation, while Adbry may cause upper respiratory infections and pink eye.
Prices with our coupons for Dupixent vs. Adbry
Compare other Eczema drugs
Dupixent vs. AdbryDupixent vs. FasenraDupixent vs. SymbicortDupixent vs. XolairEbglyss vs. Dupixent
Eohilia vs. DupixentEucrisa vs. DupixentNucala vs. DupixentOhtuvayre vs. DupixentRinvoq vs. DupixentSkyrizi vs. DupixentTezspire vs. DupixentTremfya vs. DupixentEntyvio vs. RinvoqEticovo vs. RinvoqEucrisa vs. ClobetasolEucrisa vs. ElidelEucrisa vs. HydrocortisoneEucrisa vs. OpzeluraEucrisa vs. ProtopicEucrisa vs. TacrolimusEucrisa vs. TemovateEucrisa vs. TriamcinoloneNucala vs. FasenraNucala vs. SingulairNucala vs. XolairOlumiant vs. RinvoqOrencia vs. RinvoqRemicade vs. RinvoqRinvoq vs. Actemra
